Drug Trial News

RSS

DHA supplementation during pregnancy reduces very low birth weight and early preterm delivery

University of Kansas researchers have found that the infants of mothers who were given 600 milligrams of the omega-3 fatty acid DHA during pregnancy weighed more at birth and were less likely to be very low birth weight and born before 34 weeks gestation than infants of mothers who were given a placebo. This result greatly strengthens the case for using the dietary supplement during pregnancy.

26 Feb 2013

N-acetylcysteine improves graft survival following liver transplantation

Researchers from Italy have found that the antioxidant, N-acetylcysteine (NAC), when injected prior to harvesting of the liver, significantly improves graft survival following transplantation.

26 Feb 2013

Adynxx initiates AYX1 Phase 2 study to prevent post-surgical pain

Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in a Phase 2 study of its lead investigational drug candidate for the prevention of post-surgical pain, AYX1.

26 Feb 2013

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the first patient has been dosed in a Phase 1b clinical study of AVX-470, an oral anti-TNF antibody, for the treatment of ulcerative colitis.

25 Feb 2013

Researchers to present new results for Merck's allergy immunotherapy tablets at AAAAI meeting

Merck, known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the company's investigational allergy immunotherapy tablets (AITs) for ragweed pollen (Ambrosia artemisiifolia) and grass pollen (Phleum pratense) at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

25 Feb 2013

Non-surgical weight loss device clinical trial completes enrollment

ReShape Medical® Inc announced today that it has completed enrollment in the pivotal clinical trial for the ReShape Duo® Intragastric Balloon, one of the first non-surgical weight loss devices developed for the U.S. market.

25 Feb 2013

Circassia announces results from ToleroMune cat allergy phase II clinical study

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course of just four doses of its ToleroMune cat allergy therapy maintained improvements in patients' symptoms two years after the start of treatment.

25 Feb 2013

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.

25 Feb 2013

Ampio to initiate dose escalation run-in study for treatment of knee osteoarthritis

Ampio Pharmaceuticals, Inc. announced today that it's Phase III clinical study of Ampion™ for the treatment for osteoarthritis of the knee will include a dose-escalation run-in study as recommended by the FDA.

25 Feb 2013

Okairos to commence novel RSV vaccine Phase I clinical trial

Okairos today announced the initiation of a Phase I clinical trial evaluating a vaccine against respiratory syncytial virus (RSV), a leading cause of hospital admissions in infants and children.

25 Feb 2013

New, effective and less toxic therapeutic option for patients with HER2-positive breast cancer

Patients with HER2-positive breast cancer, a particularly aggressive form of breast cancer, now have a new, effective and less toxic therapeutic option.

24 Feb 2013

New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA-asthma programme

Tiotropium delivered once daily via Respimat significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS/LABA, irrespective of their allergic status.

24 Feb 2013

New leprosy test, experimental vaccine might hasten disease elimination, Slate reports

Slate examines a new rapid diagnostic test and an experimental vaccine for leprosy, both developed by the Infectious Disease Research Institute in Seattle, writing, "The two tools together could finally free humans from the vicious cycle of a disease that has afflicted the population for at least 4,000 years."

22 Feb 2013

NIAID-funded Phase I trial to evaluate two related candidate vaccines against shigellosis

Researchers have launched an early-stage human clinical trial of two related candidate vaccines to prevent infection with Shigella, bacteria that are a significant cause of diarrheal illness, particularly among children.

21 Feb 2013

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation announced today that Immune is initiating, following authorization from Israeli health authorities, a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe ulcerative colitis.

21 Feb 2013

Dabigatran decreases risk of recurrent venous thromboembolism

New findings from two double-blind, randomized trials, RE-MEDY and RE-SONATE, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE).

21 Feb 2013

Outcomes no better with epidural steroids for patients with spinal stenosis

For patients with spinal stenosis, epidural steroid injections (ESI) may actually lead to worse outcomes-whether or not the patient later undergoes surgery, according to a study in the February 15 issue of Spine. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

19 Feb 2013

Positive results from Neurim’s Piromelatine phase II study on insomnia

Neurim Pharmaceuticals announced today positive results from a phase II clinical study evaluating the efficacy and safety of Piromelatine (Neu-P11), a novel investigational multimodal sleep medicine developed for the treatment of patients with primary and co-morbid insomnia.

18 Feb 2013

rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women

rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with hereditary antithrombin deficiency (HD) benefit from ATryn Antithrombin (Recombinant) therapy to prevent venous thromboembolic events (VTE).

16 Feb 2013

MSU to launch levetiracetam clinical trial for treatment of African children with epilepsy

Determined to bring relief to seizure victims, a Michigan State University research team this month begins a groundbreaking clinical drug trial that could help prevent a quarter-million African children from developing epilepsy each year.

16 Feb 2013

Drug Trial News

DHA supplementation during pregnancy reduces very low birth weight and early preterm delivery

N-acetylcysteine improves graft survival following liver transplantation

Adynxx initiates AYX1 Phase 2 study to prevent post-surgical pain

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

Researchers to present new results for Merck's allergy immunotherapy tablets at AAAAI meeting

Non-surgical weight loss device clinical trial completes enrollment

Circassia announces results from ToleroMune cat allergy phase II clinical study

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

Ampio to initiate dose escalation run-in study for treatment of knee osteoarthritis

Okairos to commence novel RSV vaccine Phase I clinical trial

New, effective and less toxic therapeutic option for patients with HER2-positive breast cancer

New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA-asthma programme

New leprosy test, experimental vaccine might hasten disease elimination, Slate reports

NIAID-funded Phase I trial to evaluate two related candidate vaccines against shigellosis

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Dabigatran decreases risk of recurrent venous thromboembolism

Outcomes no better with epidural steroids for patients with spinal stenosis

Positive results from Neurim’s Piromelatine phase II study on insomnia

rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women

MSU to launch levetiracetam clinical trial for treatment of African children with epilepsy

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News